Novo Nordisk and Hims & Hers have ended their bitter legal dispute over compounded weight-loss drugs, announcing a landmark partnership that will bring branded Ozempic and Wegovy directly to the Hims telehealth platform. Under the deal, the Danish pharma giant dropped its patent infringement lawsuit, while Hims agreed to stop advertising compounded GLP-1 products.
Starting later this month, Hims customers will be able to access multiple dosages of Ozempic injections (0.5 mg, 1 mg, and 2 mg) as well as Wegovy in both injectable and oral tablet forms. The products will be offered at the same price as other telehealth platforms. Hims stock surged as much as 50% on the news, while Novo Nordisk shares in Copenhagen rose 1.7%.
The deal marks a major strategic shift for Hims, which built a fast-growing weight-loss business on cheaper compounded versions of semaglutide. Analysts say the partnership could significantly expand patient access to branded GLP-1 drugs while giving Novo Nordisk a powerful new direct-to-consumer distribution channel.
